Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
Express Pharma
APRIL 11, 2024
By selectively manipulating specific molecular processes, these therapies hold the potential to treat a wide range of diseases (e.g., This cooperation aims to accelerate the development and commercialisation of oligonucleotide-based therapies to improve quality of life for patients worldwide.
Let's personalize your content